vs

Side-by-side financial comparison of FRP HOLDINGS, INC. (FRPH) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.

Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $10.9M, roughly 1.0× FRP HOLDINGS, INC.). FRP HOLDINGS, INC. runs the higher net margin — 1.3% vs -963.6%, a 964.9% gap on every dollar of revenue. On growth, FRP HOLDINGS, INC. posted the faster year-over-year revenue change (3.6% vs -52.2%). FRP HOLDINGS, INC. produced more free cash flow last quarter ($-21.5M vs $-121.0M). Over the past eight quarters, Arcus Biosciences, Inc.'s revenue compounded faster (4.9% CAGR vs 3.8%).

FRP Advisory is a business advisory firm based in the United Kingdom, providing restructuring, corporate finance, debt advisory, forensic accounting and financial advisory and is one of the UK’s largest specialists in the area of corporate restructuring.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

FRPH vs RCUS — Head-to-Head

Bigger by revenue
RCUS
RCUS
1.0× larger
RCUS
$11.0M
$10.9M
FRPH
Growing faster (revenue YoY)
FRPH
FRPH
+55.8% gap
FRPH
3.6%
-52.2%
RCUS
Higher net margin
FRPH
FRPH
964.9% more per $
FRPH
1.3%
-963.6%
RCUS
More free cash flow
FRPH
FRPH
$99.5M more FCF
FRPH
$-21.5M
$-121.0M
RCUS
Faster 2-yr revenue CAGR
RCUS
RCUS
Annualised
RCUS
4.9%
3.8%
FRPH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FRPH
FRPH
RCUS
RCUS
Revenue
$10.9M
$11.0M
Net Profit
$139.0K
$-106.0M
Gross Margin
Operating Margin
15.4%
-1036.4%
Net Margin
1.3%
-963.6%
Revenue YoY
3.6%
-52.2%
Net Profit YoY
-91.8%
-12.8%
EPS (diluted)
$0.03
$-0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRPH
FRPH
RCUS
RCUS
Q4 25
$10.9M
$11.0M
Q3 25
$10.8M
$6.0M
Q2 25
$10.8M
$8.0M
Q1 25
$10.3M
$8.0M
Q4 24
$10.5M
$23.0M
Q3 24
$10.6M
$7.0M
Q2 24
$10.5M
$11.0M
Q1 24
$10.1M
$10.0M
Net Profit
FRPH
FRPH
RCUS
RCUS
Q4 25
$139.0K
$-106.0M
Q3 25
$662.0K
$-135.0M
Q2 25
$578.0K
$0
Q1 25
$1.7M
$-112.0M
Q4 24
$1.7M
$-94.0M
Q3 24
$1.4M
$-92.0M
Q2 24
$2.0M
$-93.0M
Q1 24
$1.3M
$-4.0M
Operating Margin
FRPH
FRPH
RCUS
RCUS
Q4 25
15.4%
-1036.4%
Q3 25
12.6%
-2366.7%
Q2 25
15.3%
-100.0%
Q1 25
22.6%
-1525.0%
Q4 24
27.7%
-447.8%
Q3 24
29.0%
-1500.0%
Q2 24
26.9%
-963.6%
Q1 24
28.4%
-160.0%
Net Margin
FRPH
FRPH
RCUS
RCUS
Q4 25
1.3%
-963.6%
Q3 25
6.1%
-2250.0%
Q2 25
5.3%
Q1 25
16.6%
-1400.0%
Q4 24
16.0%
-408.7%
Q3 24
12.8%
-1314.3%
Q2 24
19.5%
-845.5%
Q1 24
12.8%
-40.0%
EPS (diluted)
FRPH
FRPH
RCUS
RCUS
Q4 25
$0.03
$-0.88
Q3 25
$0.03
$-1.27
Q2 25
$0.03
$0.00
Q1 25
$0.09
$-1.14
Q4 24
$0.09
$-1.07
Q3 24
$0.07
$-1.00
Q2 24
$0.11
$-1.02
Q1 24
$0.07
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRPH
FRPH
RCUS
RCUS
Cash + ST InvestmentsLiquidity on hand
$222.0M
Total DebtLower is stronger
$192.6M
$99.0M
Stockholders' EquityBook value
$428.5M
$631.0M
Total Assets
$735.1M
$1.1B
Debt / EquityLower = less leverage
0.45×
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRPH
FRPH
RCUS
RCUS
Q4 25
$222.0M
Q3 25
$134.9M
$238.0M
Q2 25
$153.2M
$248.0M
Q1 25
$142.9M
$192.0M
Q4 24
$148.6M
$150.0M
Q3 24
$144.7M
$201.0M
Q2 24
$156.9M
$156.0M
Q1 24
$152.5M
$185.0M
Total Debt
FRPH
FRPH
RCUS
RCUS
Q4 25
$192.6M
$99.0M
Q3 25
$185.3M
$98.0M
Q2 25
$180.4M
$97.0M
Q1 25
$178.3M
$48.0M
Q4 24
$178.9M
$48.0M
Q3 24
$178.8M
$47.0M
Q2 24
$178.8M
Q1 24
$178.7M
Stockholders' Equity
FRPH
FRPH
RCUS
RCUS
Q4 25
$428.5M
$631.0M
Q3 25
$427.7M
$436.0M
Q2 25
$426.7M
$549.0M
Q1 25
$425.2M
$531.0M
Q4 24
$423.1M
$485.0M
Q3 24
$420.9M
$565.0M
Q2 24
$419.1M
$635.0M
Q1 24
$416.1M
$707.0M
Total Assets
FRPH
FRPH
RCUS
RCUS
Q4 25
$735.1M
$1.1B
Q3 25
$731.3M
$974.0M
Q2 25
$722.8M
$1.1B
Q1 25
$717.1M
$1.2B
Q4 24
$728.5M
$1.1B
Q3 24
$726.9M
$1.3B
Q2 24
$711.9M
$1.2B
Q1 24
$705.7M
$1.3B
Debt / Equity
FRPH
FRPH
RCUS
RCUS
Q4 25
0.45×
0.16×
Q3 25
0.43×
0.22×
Q2 25
0.42×
0.18×
Q1 25
0.42×
0.09×
Q4 24
0.42×
0.10×
Q3 24
0.42×
0.08×
Q2 24
0.43×
Q1 24
0.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRPH
FRPH
RCUS
RCUS
Operating Cash FlowLast quarter
$29.7M
$-120.0M
Free Cash FlowOCF − Capex
$-21.5M
$-121.0M
FCF MarginFCF / Revenue
-196.6%
-1100.0%
Capex IntensityCapex / Revenue
468.5%
9.1%
Cash ConversionOCF / Net Profit
213.50×
TTM Free Cash FlowTrailing 4 quarters
$-34.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRPH
FRPH
RCUS
RCUS
Q4 25
$29.7M
$-120.0M
Q3 25
$8.1M
$-97.0M
Q2 25
$8.7M
$-133.0M
Q1 25
$4.5M
$-132.0M
Q4 24
$29.0M
$-100.0M
Q3 24
$6.3M
$26.0M
Q2 24
$12.2M
$-94.0M
Q1 24
$2.9M
$-2.0M
Free Cash Flow
FRPH
FRPH
RCUS
RCUS
Q4 25
$-21.5M
$-121.0M
Q3 25
$-16.9M
Q2 25
$2.6M
Q1 25
$1.4M
$-133.0M
Q4 24
$-22.2M
$-101.0M
Q3 24
$-28.2M
$25.0M
Q2 24
$5.9M
Q1 24
$-3.3M
$-6.0M
FCF Margin
FRPH
FRPH
RCUS
RCUS
Q4 25
-196.6%
-1100.0%
Q3 25
-157.0%
Q2 25
24.0%
Q1 25
13.6%
-1662.5%
Q4 24
-210.9%
-439.1%
Q3 24
-265.7%
357.1%
Q2 24
56.0%
Q1 24
-32.6%
-60.0%
Capex Intensity
FRPH
FRPH
RCUS
RCUS
Q4 25
468.5%
9.1%
Q3 25
232.0%
0.0%
Q2 25
55.9%
0.0%
Q1 25
30.1%
12.5%
Q4 24
486.1%
4.3%
Q3 24
325.1%
14.3%
Q2 24
60.3%
0.0%
Q1 24
61.2%
40.0%
Cash Conversion
FRPH
FRPH
RCUS
RCUS
Q4 25
213.50×
Q3 25
12.21×
Q2 25
15.00×
Q1 25
2.63×
Q4 24
17.18×
Q3 24
4.65×
Q2 24
5.96×
Q1 24
2.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRPH
FRPH

Other$5.6M51%
Multifamily Segment$5.3M49%

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

Related Comparisons